Keros Therapeutics's total assets for Q1 2025 were $784.56M, an increase of 27.39% from the previous quarter. KROS total liabilities were $55.69M for the fiscal quarter, a 25.62% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.